Testing the Drug Ceritinib for Meningiomas That Came Back
Original title: Ceritinib Treatment for Recurrent Meningiomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a mid stage study, so the drug is still being tested in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests whether a drug called ceritinib can slow meningiomas that have come back.
Who this trial is for. This trial is for people whose grade I or grade II meningioma has come back. They take a dose of ceritinib each day for about two years, with clinic visits about every 2 months.
Where it stands. The trial has not reported results. It is looking at whether ceritinib can slow or stop the tumor from growing or coming back. It is also looking at how safe the drug is for these patients. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, you could ask your care team about it. They know your case and can say whether it makes sense to look into.
What it doesn't mean: This does not mean ceritinib works for meningioma. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, October 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.